NOMAD intends to develop and commercialize its products in partnership with leading industry companies. The Company is focusing on rapidly expanding markets with ability and willingness to adopt new generation processes for new as well as existing products, in return for lower manufacturing costs, better ecological profiles and innovative value capture mechanisms. NOMAD's value is tied to technology platforms that reduce capital and running costs of the plant-based production to new lows, diversified portfolio of carefully chosen and innovative candidates that address attractive markets, very fast R&D engine and very short production cycle.
The founder of NOMAD is Prof. Dr. Yuri Gleba. Prior to founding NOMAD in 2008, Dr. Gleba co-founded two other biotech companies, Icon Genetics (Germany, USA) and Phytomedics (USA). He has been the CEO of Icon Genetics since its inception in 1999 and he has brought it to a successful exit in 2006 by selling the company to Bayer AG; he continues to manage it now. In addition to being an entrepreneur, Dr. Gleba has over 30 years of experience in successful management of academic/corporate R&D projects. He is a well respected scientist and inventor as evidenced by his more than 200 research papers, books and over 30 patent families and election to six national and international academies of science. Over the next few months, NOMAD intends to build a team of managers that have the necessary qualifications.
|SOURCE NOMAD Bioscience GmbH|
Copyright©2008 PR Newswire.
All rights reserved